Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Simone, Giovanni ^a   Mangia, Anita ^a   Malfettone, Andrea ^a   Rubini, Vincenza ^a   Siciliano, Michele ^a   Di Benedetto, Anna ^b   Terrenato, Irene ^b   Novelli, Flavia ^c   Mottolese, Marcella ^b  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c ENEA C R CASACCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; BIOTIN; CHROMOGENIC SUBSTRATE; DIAGNOSTIC AGENT; DIGOXIGENIN; EGFR PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; ASPIRATION CYTOLOGY; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 7; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COPY NUMBER VARIATION; FEASIBILITY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG METASTASIS; LUNG NODULE; LUNG NON SMALL CELL CANCER; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; ANEUPLOIDY; CHEMISTRY; COLORECTAL TUMOR; COMPARATIVE STUDY; EVALUATION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; IN SITU HYBRIDIZATION; ITALY; LUNG TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BIOPSY, FINE-NEEDLE; BIOTIN; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOGENIC COMPOUNDS; CHROMOSOMES, HUMAN, PAIR 7; COLORECTAL NEOPLASMS; DIGOXIGENIN; FEASIBILITY STUDIES; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; ITALY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 77956509378     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-125     Document Type: Article

References (31)

1. Signaling through the epidermal growth factor receptor during the development of malignancy. JR Grandis JC Sok, Pharmacol Ther 2004 102 37 46 10.1016/j.pharmthera.2004.01.002 15056497
2. The ErbB receptors and their role in cancer progression. T Holbro G Civenni NE Hynes, Exp Cell Res 2003 284 99 110 10.1016/S0014-4827(02)00099-X 12648469
3. Epidermal growth factor receptor mutations in lung cancer. SV Sharma DW Bell J Settleman DA Haber, Nat Rev Cancer 2007 7 169 181 10.1038/nrc2088 17318210
4. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Tabernero CE Van E az-Rubio A Cervantes Y Humblet T Andre JL Van Laethem P Soulie E Casado C Verslype JS Valera G Tortora F Ciardiello O Kisker GA de, J Clin Oncol 2007 25 5225 5232 10.1200/JCO.2007.13.2183 18024868
5. Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. M Peeters J Balfour D Arnold, Aliment Pharmacol Ther 2008 28 269 281 10.1111/j.1365-2036.2008.03717.x 19086328
6. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. PS Sharma R Sharma T Tyagi, Curr Pharm Des 2009 15 758 776 10.2174/138161209787582219 19275641
7. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization - why, when, and how? R Dziadziuszko FR Hirsch M Varella-Garcia PA Bunn Jr, Clin Cancer Res 2006 12 4409s 4415s 10.1158/1078-0432.CCR-06-0087 16857819
8. Clinical relevance of EGFR-and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. V Heinemann S Stintzing T Kirchner S Boeck A Jung, Cancer Treat Rev 2009 35 262 271 10.1016/j.ctrv.2008.11.005 19117687
9. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. FR Hirsch M Varella-Garcia F Cappuzzo J McCoy L Bemis AC Xavier R Dziadziuszko P Gumerlock K Chansky H West AF Gazdar L Crino DR Gandara WA Franklin PA Bunn Jr, Ann Oncol 2007 18 752 760 10.1093/annonc/mdm003 17317677 (Pubitemid 46523281)
10. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. M Moroni S Veronese S Benvenuti G Marrapese A Sartore-Bianchi NF Di M Gambacorta S Siena A Bardelli, Lancet Oncol 2005 6 279 286 10.1016/S1470-2045(05)70102-9 15863375
11. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan PL Harris SM Haserlat JG Supko FG Haluska DN Louis DC Christiani J Settleman DA Haber, N Engl J Med 2004 350 2129 2139 10.1056/NEJMoa040938 15118073
12. EGFR FISH in colorectal cancer: what is the current reality? M Moroni A Sartore-Bianchi S Veronese S Siena, Lancet Oncol 2008 9 402 403 10.1016/S1470-2045(08)70109-8 18452847
13. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. F Cappuzzo M Varella-Garcia G Finocchiaro M Skokan S Gajapathy C Carnaghi L Rimassa E Rossi C Ligorio TL Di AJ Holmes L Toschi G Tallini A Destro M Roncalli A Santoro PA Janne, Br J Cancer 2008 99 83 89 10.1038/sj.bjc.6604439 18577988 (Pubitemid 351920237)
14. Histology matters: individualizing treatment in non-small cell lung cancer. JW Neal, Oncologist 2010 15 3 5 10.1634/theoncologist.2009-0306 20086166
15. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. M Tanner D Gancberg LA Di D Larsimont G Rouas MJ Piccart J Isola, Am J Pathol 2000 157 1467 1472 11073807
16. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. JH Smouse ES Cibas PA Janne VA Joshi KH Zou NI Lindeman, Cancer Cytopathol 2009 117 67 72 10.1002/cncy.20011 19347832
17. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. NS Goldstein M Armin, Cancer 2001 92 1331 1346 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR14553.0.CO;2- M 11571750
18. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. L Daniele L Macri M Schena D Dongiovanni L Bonello E Armando L Ciuffreda O Bertetto G Bussolati A Sapino, Mol Cancer Ther 2007 6 1223 1229 10.1158/1535-7163.MCT-06-0719 17406029
19. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era. A Vocaturo F Novelli M Benevolo G Piperno F Marandino AM Cianciulli R Merola RP Donnorso I Sperduti S Buglioni M Mottolese, Oncologist 2006 11 878 886 10.1634/theoncologist.11-8-878 16951391
20. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. LM Sholl IA John YP Chou MT Wu YG Goan L Su YT Huang DC Christiani LR Chirieac, Mod Pathol 2007 20 1028 1035 10.1038/modpathol.3800946 17673923
21. Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. JB Hoag A Azizi TJ Doherty J Lu RE Willis ME Lund, J Exp Clin Cancer Res 2009 28 113 10.1186/1756-9966-28-113 19682368
22. A reevaluation of the clinical significance of histological subtyping of non - small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. G Rossi G Pelosi P Graziano M Barbareschi M Papotti, Int J Surg Pathol 2009 17 206 218 10.1177/1066896909336178 19443885
23. Lung cancer - where are we today? Current advances in staging and nonsurgical treatment. SG Spiro JC Porter, Am J Respir Crit Care Med 2002 166 1166 1196 10.1164/rccm.200202-070SO 12403687
24. EGFR antagonists in cancer treatment. F Ciardiello G Tortora, N Engl J Med 2008 358 1160 1174 10.1056/NEJMra0707704 18337605
25. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. ES Kim V Hirsh T Mok MA Socinski R Gervais YL Wu LY Li CL Watkins MV Sellers ES Lowe Y Sun ML Liao K Osterlind M Reck AA Armour FA Shepherd SM Lippman JY Douillard, Lancet 2008 372 1809 1818 10.1016/S0140-6736(08)61758-4 19027483
26. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. L Crino F Cappuzzo P Zatloukal M Reck M Pesek JC Thompson HE Ford FR Hirsch M Varella-Garcia S Ghiorghiu EL Duffield AA Armour G Speake M Cullen, J Clin Oncol 2008 26 4253 4260 10.1200/JCO.2007.15.0672 18779612
27. Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer. R Morinaga I Okamoto Y Fujita T Arao M Sekijima K Nishio H Ito M Fukuoka J Kadota K Nakagawa, Cancer Sci 2008 99 2455 2460 10.1111/j.1349-7006.2008.00962.x 18957054
28. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. A Horiike H Kimura K Nishio F Ohyanagi Y Satoh S Okumura Y Ishikawa K Nakagawa T Horai M Nishio, Chest 2007 131 1628 1634 10.1378/chest.06-1673 17565015
29. The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis. R Gupta AM Dastane R McKenna AM Marchevsky, Hum Pathol 2009 40 356 365 10.1016/j.humpath.2008.08.008 18976796
30. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. A Sartore-Bianchi M Moroni S Veronese C Carnaghi E Bajetta G Luppi A Sobrero C Barone S Cascinu G Colucci E Cortesi M Nichelatti M Gambacorta S Siena, J Clin Oncol 2007 25 3238 3245 10.1200/JCO.2007.11.5956 17664472
31. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. C Campanella M Mottolese A Cianciulli A Torsello R Merola I Sperduti E Melucci S Conti MG Diodoro M Zeuli G Paoletti F Cognetti C Garufi, J Transl Med 2010 8 36 10.1186/1479-5876-8-36 20398370